感染

订阅

MedSci主页 / 所有栏目 / 感染

RECARBRIO（亚胺培南、西司他丁和雷巴坦）或能“力克”呼吸机相关细菌性肺炎

2020-05-06 Allan MedSci原创

细菌性肺炎Recarbrio亚胺培南
关注

RESTORE-IMI 2是一项随机、对照、双盲的III期临床试验，旨在评估RECARBRIO治疗成人医院获得性或呼吸相关细菌性肺炎。

默克公司今日宣布了RESTORE-IMI 2的结果，RESTORE-IMI 2是一项随机、对照、双盲的III期临床试验，旨在评估RECARBRIO（亚胺培南、西司他丁和雷巴坦）治疗成人医院获得性或呼吸机相关细菌性肺炎（HABP/VABP）的有效性。结果表明，在研究的主要终点和次要终点上，RECARBRIO与哌拉西林和他唑巴坦（PIP/TAZ）相比，具有非劣势。2020年2月，美国FDA接受了RECARBRIO治疗该类患者的补充新药申请（sNDA）。

默克研究实验室传染病学副总裁Joan Butterton博士说：“我们很高兴地发布RESTORE-IMI 2临床试验的结果，该结果进一步证明了RECARBRIO治疗HABP/VABP的潜力”。

在该研究中，113个临床试验中心的537位患者按1：1比例随机分配，分别接受RECARBRIO或PIP/TAZ。主要终点是第28天的全因死亡率，次要终点是早期随访（完成治疗后7至14天）的临床反应。

 

原始出处：

https://www.firstwordpharma.com/node/1721738?tsid=4

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1763369, encodeId=8f261e63369a3, content=<a href='/topic/show?id=6ec1253186b' target=_blank style='color:#2F92EE;'>#他丁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25318, encryptionId=6ec1253186b, topicName=他丁)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d6637506150, createdName=ms2694732865965676, createdTime=Wed Oct 07 07:43:58 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036541, encodeId=4d7e2036541ab, content=<a href='/topic/show?id=28002431145' target=_blank style='color:#2F92EE;'>#亚胺培南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24311, encryptionId=28002431145, topicName=亚胺培南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Mon Jun 08 18:43:58 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253282, encodeId=d6261253282f1, content=<a href='/topic/show?id=909339652f5' target=_blank style='color:#2F92EE;'>#呼吸机#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39652, encryptionId=909339652f5, topicName=呼吸机)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri May 08 13:43:58 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469820, encodeId=bdfc1469820cb, content=<a href='/topic/show?id=9a5ee80979f' target=_blank style='color:#2F92EE;'>#细菌性肺炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78097, encryptionId=9a5ee80979f, topicName=细菌性肺炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52a57073433, createdName=pcw108, createdTime=Fri May 08 13:43:58 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581023, encodeId=f84a15810239d, content=<a href='/topic/show?id=2c161523336' target=_blank style='color:#2F92EE;'>#Recarbrio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15233, encryptionId=2c161523336, topicName=Recarbrio)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=890416693647, createdName=12498a1cm72暂无昵称, createdTime=Fri May 08 13:43:58 CST 2020, time=2020-05-08, status=1, ipAttribution=)]
    2020-10-07 ms2694732865965676

    #他丁#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1763369, encodeId=8f261e63369a3, content=<a href='/topic/show?id=6ec1253186b' target=_blank style='color:#2F92EE;'>#他丁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25318, encryptionId=6ec1253186b, topicName=他丁)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d6637506150, createdName=ms2694732865965676, createdTime=Wed Oct 07 07:43:58 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036541, encodeId=4d7e2036541ab, content=<a href='/topic/show?id=28002431145' target=_blank style='color:#2F92EE;'>#亚胺培南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24311, encryptionId=28002431145, topicName=亚胺培南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Mon Jun 08 18:43:58 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253282, encodeId=d6261253282f1, content=<a href='/topic/show?id=909339652f5' target=_blank style='color:#2F92EE;'>#呼吸机#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39652, encryptionId=909339652f5, topicName=呼吸机)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri May 08 13:43:58 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469820, encodeId=bdfc1469820cb, content=<a href='/topic/show?id=9a5ee80979f' target=_blank style='color:#2F92EE;'>#细菌性肺炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78097, encryptionId=9a5ee80979f, topicName=细菌性肺炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52a57073433, createdName=pcw108, createdTime=Fri May 08 13:43:58 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581023, encodeId=f84a15810239d, content=<a href='/topic/show?id=2c161523336' target=_blank style='color:#2F92EE;'>#Recarbrio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15233, encryptionId=2c161523336, topicName=Recarbrio)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=890416693647, createdName=12498a1cm72暂无昵称, createdTime=Fri May 08 13:43:58 CST 2020, time=2020-05-08, status=1, ipAttribution=)]
    2020-06-08 shanyongle

    #亚胺培南#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1763369, encodeId=8f261e63369a3, content=<a href='/topic/show?id=6ec1253186b' target=_blank style='color:#2F92EE;'>#他丁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25318, encryptionId=6ec1253186b, topicName=他丁)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d6637506150, createdName=ms2694732865965676, createdTime=Wed Oct 07 07:43:58 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036541, encodeId=4d7e2036541ab, content=<a href='/topic/show?id=28002431145' target=_blank style='color:#2F92EE;'>#亚胺培南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24311, encryptionId=28002431145, topicName=亚胺培南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Mon Jun 08 18:43:58 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253282, encodeId=d6261253282f1, content=<a href='/topic/show?id=909339652f5' target=_blank style='color:#2F92EE;'>#呼吸机#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39652, encryptionId=909339652f5, topicName=呼吸机)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri May 08 13:43:58 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469820, encodeId=bdfc1469820cb, content=<a href='/topic/show?id=9a5ee80979f' target=_blank style='color:#2F92EE;'>#细菌性肺炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78097, encryptionId=9a5ee80979f, topicName=细菌性肺炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52a57073433, createdName=pcw108, createdTime=Fri May 08 13:43:58 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581023, encodeId=f84a15810239d, content=<a href='/topic/show?id=2c161523336' target=_blank style='color:#2F92EE;'>#Recarbrio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15233, encryptionId=2c161523336, topicName=Recarbrio)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=890416693647, createdName=12498a1cm72暂无昵称, createdTime=Fri May 08 13:43:58 CST 2020, time=2020-05-08, status=1, ipAttribution=)]
    2020-05-08 Boyinsh

    #呼吸机#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1763369, encodeId=8f261e63369a3, content=<a href='/topic/show?id=6ec1253186b' target=_blank style='color:#2F92EE;'>#他丁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25318, encryptionId=6ec1253186b, topicName=他丁)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d6637506150, createdName=ms2694732865965676, createdTime=Wed Oct 07 07:43:58 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036541, encodeId=4d7e2036541ab, content=<a href='/topic/show?id=28002431145' target=_blank style='color:#2F92EE;'>#亚胺培南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24311, encryptionId=28002431145, topicName=亚胺培南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Mon Jun 08 18:43:58 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253282, encodeId=d6261253282f1, content=<a href='/topic/show?id=909339652f5' target=_blank style='color:#2F92EE;'>#呼吸机#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39652, encryptionId=909339652f5, topicName=呼吸机)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri May 08 13:43:58 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469820, encodeId=bdfc1469820cb, content=<a href='/topic/show?id=9a5ee80979f' target=_blank style='color:#2F92EE;'>#细菌性肺炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78097, encryptionId=9a5ee80979f, topicName=细菌性肺炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52a57073433, createdName=pcw108, createdTime=Fri May 08 13:43:58 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581023, encodeId=f84a15810239d, content=<a href='/topic/show?id=2c161523336' target=_blank style='color:#2F92EE;'>#Recarbrio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15233, encryptionId=2c161523336, topicName=Recarbrio)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=890416693647, createdName=12498a1cm72暂无昵称, createdTime=Fri May 08 13:43:58 CST 2020, time=2020-05-08, status=1, ipAttribution=)]
    2020-05-08 pcw108

    #细菌性肺炎#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1763369, encodeId=8f261e63369a3, content=<a href='/topic/show?id=6ec1253186b' target=_blank style='color:#2F92EE;'>#他丁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25318, encryptionId=6ec1253186b, topicName=他丁)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d6637506150, createdName=ms2694732865965676, createdTime=Wed Oct 07 07:43:58 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036541, encodeId=4d7e2036541ab, content=<a href='/topic/show?id=28002431145' target=_blank style='color:#2F92EE;'>#亚胺培南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24311, encryptionId=28002431145, topicName=亚胺培南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Mon Jun 08 18:43:58 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253282, encodeId=d6261253282f1, content=<a href='/topic/show?id=909339652f5' target=_blank style='color:#2F92EE;'>#呼吸机#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39652, encryptionId=909339652f5, topicName=呼吸机)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri May 08 13:43:58 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469820, encodeId=bdfc1469820cb, content=<a href='/topic/show?id=9a5ee80979f' target=_blank style='color:#2F92EE;'>#细菌性肺炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78097, encryptionId=9a5ee80979f, topicName=细菌性肺炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52a57073433, createdName=pcw108, createdTime=Fri May 08 13:43:58 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581023, encodeId=f84a15810239d, content=<a href='/topic/show?id=2c161523336' target=_blank style='color:#2F92EE;'>#Recarbrio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15233, encryptionId=2c161523336, topicName=Recarbrio)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=890416693647, createdName=12498a1cm72暂无昵称, createdTime=Fri May 08 13:43:58 CST 2020, time=2020-05-08, status=1, ipAttribution=)]
    2020-05-08 12498a1cm72暂无昵称

    #Recarbrio#

    0

相关资讯

细菌性肺炎治疗遭遇挫折：已停止Murepavadin静脉注射制剂的III期PRISM研究

Polyphor公司近日宣布，已决定停止Murepavadin静脉注射制剂的III期PRISM研究。Murepavadin预计用于医院获得性和呼吸机相关细菌性肺炎（HABP/VABP）。通过对PRISM研究中所有患者的分析，已经证实了患者血清中肌酸酐浓度升高，表明急性肾损伤的频率高于预期。

PNAS：流感继发细菌性肺炎研究获进展

流感是历史上造成人类死亡最多的疾病之一，而其中约90%的死亡病例的死因是继发细菌性肺炎。中科院微生物研究所王北难课题组日前在美国《国家科学院院刊》发表最新研究结果，揭示了病毒和细菌与宿主在致病机制中的相互关系，以及流感病毒与细菌性肺炎相关的分子机制，为预防细菌性肺炎和控制流感死亡率提供了不同的角度和新药物靶点。 据介绍，虽然流感病毒继发的肺部细菌感染现象被人们广泛关注，但其分子机制仍不清

细菌性肺炎 VS 病毒性肺炎，判断就是这么简单！

AHA2018：细菌性肺炎比病毒性肺炎对心脏的危害更大

美国盐湖城山间医学中心心脏研究所发表研究称，细菌性肺炎患者的心脏并发症比病毒性肺炎患者更严重。 研究人员发现，细菌性肺炎的患者比病毒性肺炎的患者心脏病发作、中风或死亡的风险高出60%。

Merck的抗生素Zerbaxa获得了FDA批准用于治疗医院获得性和呼吸机相关细菌性肺炎

美国食品和药物管理局宣布，默克公司的抗生素Zerbaxa（头孢唑嗪/他唑巴坦）被授权用于18岁及以上患有医院获得性细菌性肺炎和呼吸机相关细菌性肺炎（HABP / VABP）的患者。

PNAS：中科院发现流感容易引发肺炎的分子机制

流感病毒感染之后会让宿主更容易患上细菌性肺炎。这种共感染（coinfection）现象也是流感大流行时造成患者死亡的主要原因。然而，人们此前并不清楚这种现象背后的具体分子机制。中科院微生物研究所的研究团队发现，甲型流感病毒（IAV）的神经氨酸酶（NA）能够通过激活TGF-β上调粘附分子（比如纤连蛋白和整合蛋白）的表达，帮助致病菌粘附在宿主细胞上。这一成果发表在近期的美国国家科学院院刊PNA

拓展阅读

细菌性、病毒性及支原体肺炎CT特征

肺炎是因各种因素所引起的一种气道终末端或者肺泡与肺间质的炎性反应，最常见的致病因素主要包括细菌、病毒和支原体等。

肺结节频发，这4类人一定要定期检查

良性肺结节，大多是由于细菌性肺炎、真菌性肺炎、肺纤维化、病毒性肺炎等引起的，一般较稳定，不用过分担心，定期随访就可以了。

探案丨双肺阴影竟为TA？小小细节解迷团

一起来探案！

AJRCCM：新冠肺炎机械通气患者继发细菌性肺炎的患病率？

插管时基于指南的经验性抗生素管理导致抗生素过度使用。

细菌性肺炎治疗遭遇挫折：已停止Murepavadin静脉注射制剂的III期PRISM研究

Polyphor公司近日宣布，已决定停止Murepavadin静脉注射制剂的III期PRISM研究。Murepavadin预计用于医院获得性和呼吸机相关细菌性肺炎（HABP/VABP）。通过对PRISM研究中所有患者的分析，已经证实了患者血清中肌酸酐浓度升高，表明急性肾损伤的频率高于预期。

Merck的抗生素Zerbaxa获得了FDA批准用于治疗医院获得性和呼吸机相关细菌性肺炎

美国食品和药物管理局宣布，默克公司的抗生素Zerbaxa（头孢唑嗪/他唑巴坦）被授权用于18岁及以上患有医院获得性细菌性肺炎和呼吸机相关细菌性肺炎（HABP / VABP）的患者。